Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Objective: Bone marrow-derived mesenchymal stem cells (BM-MSC) migrate to primary tumours and drive tumour progression. This study aimed to identify the molecular mechanisms associated with these heterotypic cellular interactions and analyse their relevance in colorectal cancer (CRC). Design: Paracrine interactions of BM-MSC with CRC cells were studied using collagen invasion assays, cell counts, flow cytometric cell-cycle analysis and tumour xenograft models. The role of neuregulin 1 (NRG1) and the human epidermal growth factor receptor (HER) family pathways were investigated using tyrosine kinase assays, mass spectrometry, pharmacological inhibition, antibody-mediated neutralisation and RNA interference. Transmembrane neuregulin 1 (tNRG1), HER2 and HER3 expression was analysed in primary CRC (n=54), adjacent normal colorectal tissues (n=4), liver metastases (n=3) and adjacent normal liver tissues (n=3) by immunohistochemistry. Results: BM-MSC stimulate invasion, survival and tumorigenesis of CRC through the release of soluble NRG1, activating the HER2/HER3-dependent PI3K/AKT signalling cascade in CRC cells. Similarly, tumour-associated mesenchymal cells (T-MC) in CRC demonstrate high tNRG1 expression, which is significantly associated with advanced Union for International Cancer Control stage (p=0.005) and invasion depth (p=0.04) and decreased 5-year progression-free survival (p=0.01). HER2 and HER3 show membrane localisation in cancer cells of CRC tissue. Conclusion: Paracrine NRG1/HER3 signals initiated by BM-MSC and T-MC promote CRC cell progression, and high tNRG1 expression is associated with poor prognosis in CRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974 · cited 1×
“One of the best characterised targets of PI3K is AKT kinase, which regulates cell survival, cytoskeletal rearrangements and invasion.(13) Accumulating data suggest that HER3 expression is associated with poor prognosis in several cancers, including colon cancer.”
BackgroundBcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death
Oltval, Z. N., Milliman, C. L., & Korsmeyer, S. J. (1993) · Cell · doi:10.1016/0092-8674(93)90509-o · Cited by 6,003
Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche
Kaplan, R. N., Riba, R. D., Zacharoulis, S., Bramley, A. H., Vincent, L., Costa, C., MacDonald, D. D., Jin, D. K., Shido, K., Kerns, S. A., et al. (2005) · Nature · doi:10.1038/nature04186 · Cited by 3,288
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
Karnoub, A. E., Dash, A. B., Vo, A. P., Sullivan, A., Brooks, M. W., Bell, G. W., Richardson, A. L., Polyak, K., Tubo, R., & Weinberg, R. A. (2007) · Nature · doi:10.1038/nature06188 · Cited by 3,206
Role of tissue stroma in cancer cell invasion
De Wever, O., & Mareel, M. (2003) · The Journal of Pathology · doi:10.1002/path.1398 · Cited by 1,042 · cited 1×
“Tumour progression involves complex multicellular interactions between cancer cells and stromal cells.(2) In mice, bone marrow-derived mesenchymal stem cells (BM-MSC) migrate to colon tumour xenografts and are a source of tumour-associated mesenchymal cells (T-MC), which stimulate cancer progression.”
BackgroundNeuregulin 1 in neural development, synaptic plasticity and schizophrenia
Mei, L., & Xiong, W.-C. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2392 · Cited by 1,030 · cited 1×
“18 Alternative splicing and regulation through multiple promoters produce at least 30 different NRG1 isoforms, grouped into six types (IeVI) with a distinct N-terminal region.(19) Most isoforms are synthesised as transmembrane precursors and are released as soluble factors by cell surface proteases, such as tumour nec…”
BackgroundBreast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs
Oskarsson, T., Acharyya, S., Zhang, X. H.-F., Vanharanta, S., Tavazoie, S. F., Morris, P. G., Downey, R. J., Manova-Todorova, K., Brogi, E., & Massagué, J. (2011) · Nature Medicine · doi:10.1038/nm.2379 · Cited by 869
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab
Yonesaka, K., Zejnullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., Ercan, D., Rogers, A., Roncalli, M., Takeda, M., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002442 · Cited by 663
De Wever, O., Nguyen, Q., Van Hoorde, L., Bracke, M., Bruyneel, E., Gespach, C., & Mareel, M. (2004) · The FASEB Journal · doi:10.1096/fj.03-1110fje · Cited by 402 · cited 3×
“Other sources include resident fibroblasts, that produce tenascin C (TNC) and hepatocyte growth factor (HGF) as proinvasive factors for CRC cells.(23) Accordingly, in our experiments, CM activates c-Met, the receptor for HGF, in HCT8/E11 cells, which is not the case for CM, as revealed by RTK screening (see supplement…”
BackgroundMethodInfluentialSelf-citationMesenchymal stem cells enhance growth and metastasis of colon cancer
Shinagawa, K., Kitadai, Y., Tanaka, M., Sumida, T., Kodama, M., Higashi, Y., Tanaka, S., Yasui, W., & Chayama, K. (2010) · International Journal of Cancer · doi:10.1002/ijc.25440 · Cited by 308
An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation
Schoeberl, B., Faber, A. C., Li, D., Liang, M.-C., Crosby, K., Onsum, M., Burenkova, O., Pace, E., Walton, Z., Nie, L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3145 · Cited by 264
Wilson, T. R., Lee, D. Y., Berry, L., Shames, D. S., & Settleman, J. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.07.011 · Cited by 161
Cited by
Mesenchymal stem cell-derived exosomes as a new therapeutic strategy for liver diseases
Lou, G., Chen, Z., Zheng, M., & Liu, Y. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.63 · Cited by 601
The Pros and Cons of Mesenchymal Stem Cell-Based Therapies
Musiał-Wysocka, A., Kot, M., & Majka, M. (2019) · Cell Transplantation · doi:10.1177/0963689719837897 · Cited by 534
Tumour-associated mesenchymal stem/stromal cells: emerging therapeutic targets
Shi, Y., Du, L., Lin, L., & Wang, Y. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.193 · Cited by 460
Lin, R., Wang, S., & Zhao, R. C. (2013) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-013-1746-z · Cited by 310
Zhuang, W.-Z., Lin, Y.-H., Su, L.-J., Wu, M.-S., Jeng, H.-Y., Chang, H.-C., Huang, Y.-H., & Ling, T.-Y. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00725-7 · Cited by 258
Metadata
- Authors
- De Boeck, A., Pauwels, P., Hensen, K., Rummens, J.-L., Westbroek, W., Hendrix, A., Maynard, D., Denys, H., Lambein, K., Braems, G., Gespach, C., Bracke, M., & Wever, O. D.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2012-04-25
- Volume
- 62
- Issue
- 4
- Pages
- 550-560
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2102810283
- Cited by
- 167
- References
- 13
- FWCI
- 5.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.